![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.205.965 |
Chemical and physical data | |
Formula | C25H21F4N3O3 |
Molar mass | 487.455 g·mol−1 |
3D model ( JSmol) | |
| |
|
AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca [1] and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease. [2] [3] [4] [5] [6]
It has completed a phase II clinical trial. [7]
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.205.965 |
Chemical and physical data | |
Formula | C25H21F4N3O3 |
Molar mass | 487.455 g·mol−1 |
3D model ( JSmol) | |
| |
|
AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca [1] and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease. [2] [3] [4] [5] [6]
It has completed a phase II clinical trial. [7]